Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R



TSX:CXR.R - Post by User

Comment by Marcel7on Jun 04, 2016 5:38pm
77 Views
Post# 24934699

RE:What action could UK government take?

RE:What action could UK government take?Damn autocorrect. Offending not "off encoding"...corrected in quotes.
Marcel7 wrote: This from the daily mail article: A Department of Health spokesman said: 'No pharmaceutical company should be exploiting the NHS. The Competition and Markets Authority is already investigating a potential abuse of generics pricing, and as part of a public consultation we have asked for views on government powers to limit the prices of generic medicines where there is no competitive market.' Read two things here. One: they are investigating "A" potential abuse of generics pricing. My understanding is "a" typically means one. Two : "WHERE THERE IS NO COMPETITIVE MARKET." I believe that most AMCO drugs do have a competitor. Furthermore, at what price are these drugs profitable? What if usage has dropped off and it has become somewhat of a niche product? You cannot force a company to produce these products at a loss. If they change the pricing environment it has consequences on availability of these niche medicines or dosages. My understanding is that the UK already has pretty strict regulations regarding pricing, this was a loophole, not the norm, and given a large portfolio of drugs it is not likely many are impacted. Does anyone have access to The Times article? Does it have a more detailed list of the alleged offending drugs? We can then cross reference these against CXR/AMCO portfolio to see if there is any relevance at all. Marcel


<< Previous
Bullboard Posts
Next >>